Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dasatinib

FDA-approved product (tablet, oral), marketed as Dasatinib, Phyrago, Sprycel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Dasatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute lymphoblastic leukemia
  • B-cell acute lymphoblastic leukemia
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Cancer
  • Childhood acute lymphoblastic leukemia
  • Childhood cancer
  • Chronic myelogenous leukemia
  • Lymphoblastic lymphoma
  • Lymphoid leukemia
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bcr-abl tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dasatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dasatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study

    NCT07000734 · start 2025-07-28

    Registered record
    Registry ID
    NCT07000734
    Conditions
    Aging; Cognitive Decline; Older Adults; Cardiovascular; Sedentary Behaviors; Immune Senescence; Motor Function
    Interventions
    Risk managment; Dasatinib; Quercetin (dietary supplement); Vortioxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2025-07-28
    Completion
    2026-04-30
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAging; Cognitive Decline; Older Adults; Cardiovascular +3 more
    InterventionRisk managment; Dasatinib; Quercetin (dietary supplement); Vortioxetine
    PhasePhase 2
    Registry statusCompleted

  • A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    NCT06124157 · start 2025-05-30

    Registered record
    Registry ID
    NCT06124157
    Conditions
    B Acute Lymphoblastic Leukemia
    Interventions
    Biospecimen Collection; Blinatumomab; Bone Marrow Biopsy; Calaspargase Pegol; Cyclophosphamide; Cytarabine; Dasatinib; Daunorubicin; Doxorubicin; Echocardiography Test; Imatinib; Leucovorin; Mercaptopurine; Methotrexate; Multigated Acquisition Scan; Pegaspargase; Prednisolone; Prednisone; Radiation Therapy; Thioguanine; Vincristine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-30
    Completion
    2030-12-01
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB Acute Lymphoblastic Leukemia
    InterventionBiospecimen Collection; Blinatumomab; Bone Marrow Biopsy; Calaspargase Pegol +17 more
    PhasePhase 2
    Registry statusRecruiting

  • Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

    NCT07152041 · start 2025-03-28

    Registered record
    Registry ID
    NCT07152041
    Conditions
    Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+); Childhood Leukemia, Acute Lymphoblastic
    Interventions
    olverembatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-03-28
    Completion
    2030-06
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+); Childhood Leukemia, Acute Lymphoblastic
    Interventionolverembatinib
    PhasePhase 3
    Registry statusRecruiting

  • Pilot Trial for Treatment of Recurrent Glioblastoma

    NCT05432518 · start 2023-06-27

    Registered record
    Registry ID
    NCT05432518
    Conditions
    Glioblastoma; Recurrent Disease; Recurrent Glioblastoma
    Interventions
    Afatinib; Dasatinib; Palbociclib; Everolimus; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2023-06-27
    Completion
    2027-12-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma; Recurrent Disease; Recurrent Glioblastoma
    InterventionAfatinib; Dasatinib; Palbociclib; Everolimus +1 more
    PhaseEarly phase 1
    Registry statusRecruiting

  • A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL

    NCT05026229 · start 2021-09-06

    Registered record
    Registry ID
    NCT05026229
    Conditions
    Precursor Cell Lymphoblastic Leukemia-Lymphoma; Philadelphia-Positive Acute Lymphoblastic Leukemia; ALL, Adult
    Interventions
    dasatinib plus consolidation chemotherapy with vincristine and prednisone; dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-09-06
    Completion
    2023-06-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrecursor Cell Lymphoblastic Leukemia-Lymphoma; Philadelphia-Positive Acute Lymphoblastic Leukemia; ALL, Adult
    Interventiondasatinib plus consolidation chemotherapy with vincristine and prednisone; dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine
    PhaseNot applicable
    Registry statusUnknown

  • Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

    NCT04996160 · start 2021-07-09

    Registered record
    Registry ID
    NCT04996160
    Conditions
    Acute Lymphoblastic Leukemia, Pediatric; Relapsed Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia
    Interventions
    Palbociclib; Dexamethasone; Bortezomib; Doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-07-09
    Completion
    2023-10-16
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia, Pediatric; Relapsed Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia
    InterventionPalbociclib; Dexamethasone; Bortezomib; Doxorubicin
    PhasePhase 1
    Registry statusCompleted

  • Dasatinib In Waldenström Macroglobulinemia

    NCT04115059 · start 2019-11-04

    Registered record
    Registry ID
    NCT04115059
    Conditions
    Waldenstrom Macroglobulinemia; DASATINIB
    Interventions
    Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2019-11-04
    Completion
    2021-12-31
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWaldenstrom Macroglobulinemia; DASATINIB
    InterventionDasatinib
    PhasePhase 1
    Registry statusTerminated

  • Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

    NCT03352427 · start 2017-12-06

    Registered record
    Registry ID
    NCT03352427
    Conditions
    Glioma; High Grade Glioma; Pontine Tumors
    Interventions
    Dasatinib; Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-12-06
    Completion
    2019-05-15
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioma; High Grade Glioma; Pontine Tumors
    InterventionDasatinib; Everolimus
    PhasePhase 2
    Registry statusTerminated

  • Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

    NCT02819804 · start 2017-08-17

    Registered record
    Registry ID
    NCT02819804
    Conditions
    B Acute Lymphoblastic Leukemia With t(9; 22)(q34; q11.2); BCR-ABL1; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Refractory Adult Acute Lymphoblastic Leukemia; Refractory Childhood Acute Lymphoblastic Leukemia
    Interventions
    Dasatinib; Laboratory Biomarker Analysis; Nivolumab; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2017-08-17
    Completion
    2018-08-30
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB Acute Lymphoblastic Leukemia With t(9; 22)(q34; q11.2); BCR-ABL1 +4 more
    InterventionDasatinib; Laboratory Biomarker Analysis; Nivolumab; Pharmacological Study
    PhasePhase 1
    Registry statusTerminated

  • Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

    NCT03117751 · start 2017-03-29

    Registered record
    Registry ID
    NCT03117751
    Conditions
    Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
    Interventions
    Prednisone; Vincristine; Daunorubicin; Pegaspargase; Erwinase®; Cyclophosphamide; Cytarabine; Mercaptopurine; Dasatinib; Methotrexate; Blinatumomab; Ruxolitinib; Bortezomib; Dexamethasone; Doxorubicin; Etoposide; Clofarabine; Vorinostat; Idarubicin; Nelarabine; Thioguanine; Asparaginase Erwinia chrysanthemi (recombinant)-rywn; Calaspargase Pegol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2017-03-29
    Completion
    2028-09-30
    Enrolment
    790

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
    InterventionPrednisone; Vincristine; Daunorubicin; Pegaspargase +19 more
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

    NCT02954523 · start 2016-10

    Registered record
    Registry ID
    NCT02954523
    Conditions
    EGFR Gene Mutation; Nonsmall Cell Lung Cancer
    Interventions
    Dasatinib; Osimertinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2016-10
    Completion
    2023-03-03
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEGFR Gene Mutation; Nonsmall Cell Lung Cancer
    InterventionDasatinib; Osimertinib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

    NCT04925141 · start 2016-05-10

    Registered record
    Registry ID
    NCT04925141
    Conditions
    Chronic Myelogenous Leukemia - Chronic Phase
    Interventions
    Dasatinib Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-05-10
    Completion
    2019-12-06
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myelogenous Leukemia - Chronic Phase
    InterventionDasatinib Tablets
    PhasePhase 4
    Registry statusCompleted

  • An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

    NCT02750514 · start 2016-05-09

    Registered record
    Registry ID
    NCT02750514
    Conditions
    Advanced Cancer
    Interventions
    Nivolumab; Dasatinib; Relatlimab; Ipilimumab; BMS-986205
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-05-09
    Completion
    2020-01-29
    Enrolment
    295

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer
    InterventionNivolumab; Dasatinib; Relatlimab; Ipilimumab +1 more
    PhasePhase 2
    Registry statusTerminated

  • Hematopoietic Stem Cell Transplant Survivors Study

    NCT02652052 · start 2016-03-01

    Registered record
    Registry ID
    NCT02652052
    Conditions
    Stem Cell Transplant
    Interventions
    Standard of Care - Observation Only; Group 2: Quercetin; Group 2: Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-03-01
    Completion
    2023-05-23
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStem Cell Transplant
    InterventionStandard of Care - Observation Only; Group 2: Quercetin; Group 2: Dasatinib
    PhasePhase 1
    Registry statusCompleted

  • Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

    NCT02559778 · start 2015-09

    Registered record
    Registry ID
    NCT02559778
    Conditions
    Neuroblastoma
    Interventions
    Ceritinib; dasatinib; sorafenib; vorinostat; DFMO
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2015-09
    Completion
    2035-09
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma
    InterventionCeritinib; dasatinib; sorafenib; vorinostat +1 more
    PhasePhase 2
    Registry statusRecruiting